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Ribosome profiling (Ribo-seq) has catalyzed a 
paradigm shift in our understanding of the 
translational ‘vocabulary’ of the human genome, 
discovering thousands of translated open reading 
frames (ORFs) within long non-coding RNAs and 
presumed untranslated regions of protein-coding 
genes. However, reference gene annotation projects 
have been circumspect in their incorporation of these 
ORFs due to uncertainties about their experimental 
reproducibility and physiological roles. Yet, it is 
indisputable that certain Ribo-seq ORFs make stable 
proteins, others mediate gene regulation, and many 
have medical implications. Ultimately, the absence of 
standardized ORF annotation has created a circular 
problem: while Ribo-seq ORFs remain unannotated 
by reference biological databases, this lack of 
characterisation will thwart research efforts 
examining their roles. Here, we outline the initial 
stages of a community-led effort supported by 
GENCODE / Ensembl, HGNC and UniProt to produce 





Human gene annotation is performed by several major 
reference databases. These resources are used worldwide 
to support both primary scientific research and clinical 
workflows, and knowledge gained from downstream 
applications can be used to improve the annotations in a 
reciprocal manner. It is now clear that Ribo-seq (also known 
as ribosome profiling) has the potential to be an important 
source of biological information. Ribo-seq provides a direct 
readout of mRNA translation and can therefore nominate 
translated open reading frames (ORFs) - the precise coding 
regions of our genomes - with nucleotide resolution. This 
high-throughput RNA sequencing-based method may herald 
the biggest paradigm shift in gene annotation since the 
advent of conventional RNA-seq (Figure 1A-B). 
Consequently, there is a community need for reference 
annotation of ORF translations identified by this technique. 
Yet, reference annotation projects lack expertise in this area; 
they neither generate experimental Ribo-seq data nor 
develop specific analytical software or workflows. 
Furthermore, Ribo-seq ORF discovery is a rapidly evolving 
field that provokes a range of questions on biological 
interpretation, the answers to which will directly inform the 
annotation process. As such, collaboration between the 
annotation databases and experts in the research 
community will be vital for a successful, accurate, and 
comprehensive ORF annotation that suits community needs. 
    To this end, we have initiated a community-focused 
collaboration that addresses a central question in modern-
day gene annotation: how should one approach Ribo-seq 
ORF integration? A series of conversations - mediated by 
Ensembl / GENCODE (henceforth GENCODE) - have been 
held between frontline Ribo-seq research groups and 
annotation projects, including UniProtKB / Swiss-Prot 
(henceforth UniProt) and the HUGO Gene Nomenclature 
Committee (HGNC). These efforts seek to leverage 
complementary expertise in the fields of experimental 
analysis and gene annotation, and reflect a broad, 
multinational effort including leading experts in diverse 
domains of gene and protein discovery, genome evolution, 
Ribo-seq experimental techniques, and computational 
analysis (Figure 1C). In this article, we will discuss the 
importance of, and also the challenges in, producing a 
centralized Ribo-seq ORF annotation, and present the first 
consolidated catalog of Ribo-seq ORFs supported by the 
major reference gene annotation databases. 
 
The state of play in coding sequence annotation 
A core goal of genome annotation projects is to describe the 
portion of genomic sequence that encodes protein. It may 
appear that this goal is close to being accomplished in 
humans, given that the counts of protein-coding genes in the 
GENCODE (Frankish et al., 2021; Howe et al., 2021), HGNC 
(Tweedie et al., 2021), RefSeq (O‟Leary et al., 2016) and 
UniProt (The UniProt Consortium, 2021) gene and protein 
annotation projects have stabilized at around 20,000. While 
these gene counts are not static, all four catalogs have 
incorporated only modest changes in recent years. 
Furthermore, each project now depends entirely on manual 
annotation for the addition or removal of protein-coding 
genes - i.e., the expert human evaluation of evidence 
available for gene transcription, mRNA translation and 
protein function - and such adjustments are now made in a 
largely coordinated manner (Pujar et al., 2018). Nonetheless, 
new or improved sources of evidence continue to emerge, 
from both experimental and computational genomics, and 
these have the potential to instigate new „phases‟ in 
annotation. For example, the recent expansion in availability 
of genome sequences from other species has greatly 
improved analytical power in the identification of conserved 
Coding Sequences (CDS) based on evolutionary methods 
(Lin et al., 2011), leading to the in silico detection of 
additional protein-coding genes in the last few years (Mudge 
et al., 2019). Meanwhile, modest numbers of new protein-
coding genes continue to be reported via the de novo 
detection of proteins by mass spectrometry (MS) (Ma et al., 
2014; Schwaid et al., 2013; Slavoff et al., 2013). 
    However, such progress conceals an important truth: the 
annotation of coding sequences remains difficult. While 
improved evolutionary and MS-based methods continue to 
be of great value to CDS annotation - especially when used 
in conjunction - each has its limitations. In particular, 
evolutionary methods have a potential „blindspot‟ when it 
comes to the identification of shorter and/or recently 
emerged CDSs, e.g. those that are specific to the primate 
lineage (Ruiz-Orera and Albà, 2019a; Van Oss and 
Carvunis, 2019). Furthermore, even if the coding evolution of 
a sequence is supported by conservation and constraint 
measurements, additional experimental support is required 
to confirm the production of a protein and elucidate its 
potential biological role. Similarly, developing CDS 
annotations exclusively through short peptide fragments 
obtained by MS is challenging (Nesvizhskii, 2014) and 
remains a highly extrapolative effort (Wright et al., 2016). 
The development of methods to obtain „true‟ full-length 
protein sequences would effectively resolve the difficulties of 
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Figure 1: Formation of a community consensus resource for Ribo-seq ORFs.  (A) A timeline showing the formation of this effort in 
relationship to major scientific advances in understanding these ORFs.  (B) A schematic of the main steps done in this effort.  (C) A map 
showing the participating institutions included in this effort. 
 
 
CDS annotation, and while recent advances in proteomics 
technologies hold promise for the future of protein 
sequencing (Swaminathan et al., 2018; Timp and Timp, 
2020), alternative approaches are required in the meantime.  
 
Enter Ribo-seq 
Given the challenges associated with protein annotation, the 
experimental datasets produced by Ribo-seq would seem to 
offer a major boon to annotation projects. First developed in 
2009 (Ingolia et al., 2009), Ribo-seq is an experimental 
method that isolates ribosome-bound RNA fragments for 
deep sequencing by treating cell lysates with RNase to 
degrade bulk, free-standing RNA while preserving ribosome-
bound RNA fragments of ~30 nucleotides in length. Library 
preparation and sequencing of these RNA fragments offer 
genome-wide footprints of ribosome-RNA interactions, 
enabling the possibility of detecting translated ORFs with 
sub-codon resolution (Ingolia et al., 2009, 2014; Ruiz-Orera 
and Albà, 2019a). Thus, in contrast to MS, Ribo-seq maps 
sequencing reads to the genome or transcriptome, rather 
than peptide fragments to potential protein sequences.  
    Collectively, there have been thousands of human 
genomic sites newly nominated as translated by Ribo-seq, a 
small subset of which are currently supported by peptide-
level evidence in MS data (Bazzini et al., 2014; Chen et al., 
2020; Doll et al., 2017; van Heesch et al., 2019; Martinez et 
al., 2019; Ouspenskaia et al., 2020; Prensner et al., 2021). 
Many of these regions of prospective translation reside in 
areas of the genome previously thought to be non-coding, 
and they can be categorised according to their genomic 
location and context with regard to existing annotations. Box 
1 outlines the six categories of Ribo-seq ORFs that are 
considered in this article, all of which are associated with 
protein-coding genes (uORFs, uoORFs, intORFs, dORFs 
and doORFs) and long non-coding RNAs (lncRNA-ORFs). 
Ribo-seq can also describe translations within pseudogenes 
(Pei et al., 2012; Sisu et al., 2014, 2020), i.e. loci that are 
currently believed to be defunct protein-coding genes. 
However, pseudogene translations - „pseudo-ORFs‟ - are not 
considered in the efforts outlined here due to potential 
complexities in mapping Ribo-seq data at loci that can have 
highly similar paralogs elsewhere in the genome. Although 
present at much lower numbers compared to other 
translations, Ribo-seq reads mapped onto circular RNAs 
(circRNAs) can also be detected, suggesting cap-
independent translation (van Heesch et al., 2019; Legnini et 
al., 2017; Pamudurti et al., 2017; Yang et al., 2017). 
However, reference annotation projects do not yet 
incorporate circRNAs, and the experimental evidence that 
circular transcripts are translated by ribosomes into 
„circORFs‟ (or „cORFs‟) remains a topic of ongoing debate 
(Hansen, 2020; Ho-Xuan et al., 2020). 
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Finally, Ribo-seq can also identify alternative isoforms of 
annotated proteins, including in-frame N-terminal extensions 
(e.g. as recently reported for STARD10 and ZNF281 (Na et 
al., 2018)), and internal translation initiation sites that 
produce shorter proteoforms; the latter especially will be of 
great benefit to annotation projects as they are very difficult 
to find through conservation studies. 
    Over time, a number of public resources have appeared 
that process and display Ribo-seq datasets for the benefit of 
the community: sORFs.org, for example, offers a collection 
of Ribo-seq ORFs under 100 amino acids in size for multiple 
species based on a standardized data reprocessing platform 
that includes MS data (Olexiouk et al., 2018), while GWIPS-
viz is a genome browser-style interface that displays tracks 
of publicly available Ribo-seq data aligned to the reference 
genomes. In contrast, Trips-Viz provides access to Ribo-seq 
data aligned to reference transcriptomes, and allows detailed 
analysis including ORF prediction incorporating triplet 
periodicity and MS data integration (Kiniry et al., 2019; 
Michel et al., 2018). The OpenProt (Brunet et al., 2019) and 
nORFs.org (Neville et al., 2020) databases seek to collate 
experimental support - including Ribo-seq and MS - for any 
ORF that can be extracted from the GENCODE or RefSeq 
annotation, and so to produce a theoretical catalog of the 
entire translatome. Furthermore, nORFs.org incorporates 
information on heritability and selection in human 
populations. Other projects have focused on specific 
categories of Ribo-seq ORFs; McGillivray et al, for example, 
have produced a catalog of uORFs with predicted biological 
activity (McGillivray et al., 2018).  
Box 1: A proposed standardized nomenclature and categorization of Ribo-seq ORFs 
 
We use Ribo-seq ORF to refer to translated sequences identified by the Ribo-seq assay that have not already been 
annotated by reference annotation projects. Such ORFs have also been referred to as non-canonical ORFs or 
alternative ORFs (altORFs) to reflect this lack of annotation, and more recently as novel ORFs (nORFs). The terms small 
ORF (smORF) and short ORF (sORF) are often used to describe those translations that are under a given size, typically 
100 amino acids, while newly-identified small proteins are often referred to as microproteins, micropeptides or short 
ORF-encoded polypeptides (SEPs). Ribo-seq ORFs have been traditionally sub-categorised based on their location on 
the overlapping gene on the same strand, and a variety of nomenclature terms have been used. Our work uses the 
following six terms. 
 
1. Upstream ORFs (uORFs). uORFs are located within the exons of the 5‟ untranslated region (5‟ UTR) of 
annotated protein-coding genes. Many uORFs are known to regulate the translational efficiency of the 
downstream canonical protein (Johnstone et al., 2016; McGillivray et al., 2018), for example in response to stress 
(Starck et al., 2016). Others may have roles that are independent from the downstream protein, and some have 
been shown to produce independent proteins (Cloutier et al., 2020; Huang et al., 2021; Rathore et al., 2018).  
 
 
2. Upstream overlapping ORFs (uoORFs). uoORFs are translated from the 5‟ UTR of an annotated protein-
coding gene and partially overlap its coding sequence in a different reading frame. At least some uoORFs 
regulate translation of their overlapping CDS in a manner similar to uORFs but with effects that are anticipated to 
be stronger, as the ORF terminates within the main CDS (past the CDS initiation codon) (Johnstone et al., 2016). 
Some uoORFs have been shown to produce independent proteins (Khan et al., 2020; Loughran et al., 2020).  
 
 
3. Downstream ORFs (dORFs). dORFs are located within the 3‟ UTR of annotated protein-coding genes. While 
ORFs are ubiquitous within 3‟ UTRs and can be translated using canonical translation initiation factors (Nobuta et 
al., 2020), dORFs are less commonly detected in Ribo-seq assays than uORFs, and their putative biological roles 
remain underexplored. It has been suggested that they can act as cis translational regulators (Wu et al., 2020). 
 
 
4. Downstream overlapping ORFs (doORFs). doORFs start within the genomic coordinates of an annotated CDS 
but their reading frames continue beyond the annotated CDS and terminate in the 3‟ UTR of the annotated gene. 
 
 
5. Internal out-of-frame ORFs (intORFs). intORFs - also referred to as altCDSs, nested ORFs and dual-coding 
regions - are located on the mRNA of an annotated protein-coding gene and are completely encompassed within 
the canonical CDS. However, they translate via a different reading frame, potentially generating an entirely 
distinct protein. Detection of intORFs with Ribo-seq is possible but difficult due to the convolution of triplet 
periodicity signals from two reading frames; it largely depends on the length and translation level of the intORF 
relative to the overlapping canonical CDS (Erhard et al., 2018; Michel et al., 2012). It is also challenging to 
estimate the evolutionary constraints acting on intORFs independently from those on the overlapping CDS. 
 
 
6. Long non-coding RNA ORFs (lncRNA-ORFs). lncRNA-ORFs are encoded by transcripts currently annotated 
as long non-coding RNAs (lncRNAs), including long intervening/intergenic noncoding RNAs (lincRNAs), long 
non-coding RNAs that host small RNA species (encompassing microRNAs, snoRNAs, etc), antisense RNAs, and 
others. Most lncRNAs evolve rapidly (Hezroni et al., 2015) and, accordingly, their translated ORFs often lack 
strong sequence conservation.  
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    In contrast, Ribo-seq datasets have so far had less impact 
on the reference human genome annotations produced by 
GENCODE, RefSeq and UniProt. As noted above, these 
projects now only annotate new protein-coding genes 
following manual analysis; they do not incorporate ORF 
catalogs reported in the literature or by independent 
databases such as sORFs.org in an unsupervised manner, 
and they have not developed their own pipelines for 
processing Ribo-seq data. As a result, few Ribo-seq ORFs 
have been officially named by the HGNC, (Bruford et al., 
2020), who work directly with GENCODE, RefSeq and 
UniProt. This exclusion of Ribo-seq ORFs from the reference 
annotation databases has downstream implications: virtually 
all large-scale gene-based projects, including for example 
ENCODE (ENCODE Project Consortium, 2012), gnomAD 
(Karczewski et al., 2020), and the UK BioBank (Van Hout et 
al., 2020), use reference annotation databases to support 
their projects. Therefore, such large-scale research efforts 
pass over Ribo-seq ORFs. Crucially, reference annotation 
databases also provide the common framework for the 
interpretation of human variants in the clinic, which means 
that there is at present effectively no recognised intersection 
between Ribo-seq ORFs and variation datasets in this 
setting. In short, while Ribo-seq ORFs remain absent from 
reference annotation catalogs, they will be harder for 
everyone - from individual researchers to large consortia - to 
access and use, limiting comprehensive analysis.  
    While the focus of the current article is on the annotation 
of Ribo-seq ORFs identified in human, it should be noted 
that Ribo-seq has also been used to identify translated ORFs 
in many other species, such as mouse (Ingolia et al., 2011; 
Ruiz-Orera et al., 2018), zebrafish (Bazzini et al., 2012, 
2014; Chew et al., 2013), fly (Patraquim et al., 2020), 
nematode (Stadler and Fire, 2011), plant (Hsu et al., 2016; 
Juntawong et al., 2014), yeast (Blevins et al., 2021; Brar et 
al., 2012; Carvunis et al., 2012; Durand et al., 2019; Ingolia 
et al., 2009; Smith et al., 2014; Wilson and Masel, 2011) and 
bacterial and viral genomes (Finkel et al., 2021; Fremin et 
al., 2020; Hücker et al., 2017; Stern-Ginossar et al., 2012). 
 
How to appraise Ribo-seq ORFs  
Ultimately, Ribo-seq data represents both an opportunity and 
a challenge for annotation projects. The advantage of being 
able to identify missing translated elements – and to validate 
existing coding annotations – is clear. Nonetheless, there are 
real difficulties in designing an appropriate annotation 
framework for these datasets, largely because there are 
significant questions on the precise biological interpretation 
of a given translated ORF (Box 1). Such ambiguities are in 
conflict with the remit of reference annotations to provide 
high confidence interpretations (Mudge and Harrow, 2016). 
Thus, the hesitancy to annotate Ribo-seq ORFs can also be 
explained in terms of „usability‟. Any ambiguities in an ORF 
annotation catalog would be passed on to the vast numbers 
of projects that depend on reference gene annotation, and 
this „burden of responsibility‟ is a core consideration when 
strategizing. For example, if Ribo-seq ORFs are incorporated 
into reference gene annotations, then a framework for the 
interpretation of putative disease-linked variants found within 
these features is also required.  
    A primary concern is that Ribo-seq ORFs would seem to 
challenge a key principle of gene and protein annotation, that 
„conservation = function‟. The majority of Ribo-seq ORFs do 
not exhibit strong conservation at the amino acid level or 
signatures of sequence constraints indicative of selection on 
CDS. Reference annotation projects have historically 
avoided the annotation of lineage-specific „de novo‟ proteins, 
unless clear experimental evidence for the existence of the 
protein has been provided. In addition, Ribo-seq ORFs also 
challenge the assumption that „translation = protein 
production‟. The experimental technique itself cannot 
distinguish an ORF that produces a genuine protein from an 
ORF whose translation product is quickly degraded; it only 
monitors the synthesis event, not what comes afterwards. 
This allows for a wide breadth of alternative explanations for 
the biological mechanisms of Ribo-seq ORF function, as 
outlined in Box 2. For example, certain translations - 
especially within the uORF, uoORF and dORF categories - 
have been demonstrated to impart cis gene regulatory 
effects arising from the act of translation rather than from the 
protein that is being synthesized (Andreev et al., 2015; 
Johnstone et al., 2016; Starck et al., 2016). uORFs in 
particular have been known to exist for decades - stemming 
from investigations by Kozak and others about why a CDS 
does not always employ the first AUG present in a given 
mRNA (Kozak, 1991; Lovett and Rogers, 1996) - although 
reference annotation projects have made very little progress 
in their annotation (Figure 1A).  
 
New ORFs in the light of evolution 
Sequence conservation and constraints on ORF codon 
structure across species indicate the action of purifying 
selection maintaining the protein encoded by an ORF. 
Traditional methods to assess sequence homology and 
purifying selection are size-dependent and do not work well 
with Ribo-seq ORFs, which are commonly small (Couso and 
Patraquim, 2017; Ruiz-Orera and Albà, 2019b). In contrast, 
recent methods like PhyloCSF (Lin et al., 2011) have single-
codon resolution. The recent creation of whole genome 
PhyloCSF datasets for several species led to the detection of 
a set of short human proteins conserved within the 
mammalian order, several of which have been 
experimentally characterized (Anderson et al., 2015; Cloutier 
et al., 2020; Mudge et al., 2019; Pauli et al., 2014; Rathore et 
al., 2018). However, most Ribo-seq ORFs display 
conservation limited to primates, with no evidence of 
selective constraints acting to maintain protein sequences 
(Prensner et al., 2021; Ruiz-Orera and Albà, 2019a).  
    The absence or weakness of signatures of purifying 
selection observed in Ribo-seq ORFs could suggest that 
most do not encode proteins that contribute to organismal 
fitness (Aspden et al., 2014; Gerstein et al., 2007; Ji et al., 
2015; Kaessmann, 2010; Ruiz-Orera and Albà, 2019a). 
However, purifying selection is unlikely to yield detectable 
sequence signatures on ORFs that have evolved recently de 
novo from transcribed sequences that were previously non-
coding (Van Oss and Carvunis, 2019). Most human-specific 
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and primate-specific proteins have likely evolved through this 
mechanism (Vakirlis et al., 2020a). ORFs that are so „young‟ 
in evolutionary terms may not have existed for a long enough 
time to display detectable sequence signatures of selection, 
but they could still be beneficial for fitness (Prensner et al., 
2021; Vakirlis et al., 2020b). Our knowledge that ORFs can 
also mediate gene regulation complicates matters further, 
especially as less is known about the mode and tempo of 
regulatory ORF evolution. Such ORFs could potentially be 
identified by alternative patterns of conservation, assuming 
that this regulatory effect is not specific to the human 
lineage. For instance, the nucleotide sequences encoding 
uORFs may harbor specific conserved secondary structure 
features that impact their translational efficiency or 
repressive effect against translation of the CDS (Chew et al., 
2016). Alternatively, it may be that the position of a Ribo-seq 
ORF in a transcript is conserved, i.e. that the initiation and / 
or termination codons are conserved, or that the length of 
the reading frame - although not the specific protein 
sequence - is constrained (Spealman et al., 2018). 
Numerous uORFs and dORFs have now been identified that 
are conserved between orthologous genes in vertebrates, 
despite sharing little similarity at the amino acid level 
(Bazzini et al., 2014; Chew et al., 2016; Dumesic et al., 
2019; Wu et al., 2020). It may be appropriate to consider 
ORFs with these properties as candidate regulatory 
elements. However, there can be alternative explanations for 
the observed conservation of Ribo-seq ORFs at the DNA 
level. Some intORFs, uoORFs and doORFs will inevitably 
have elevated conservation due to the presence of selection 
in the alternative CDS reading frame, while uORFs and 
dORFs can overlap with conserved non-coding sequence 
elements including RNA secondary structures, protein-RNA 
binding motifs and microRNA binding sites (Ruiz-Orera and 
Albà, 2019b). Altogether, these considerations make it very 
difficult to infer whether a Ribo-seq ORF contributes to 
organismal fitness based on its sequence evolution alone. 
 
Box 2: Interpreting Ribo-seq ORFs 
 
There are multiple possible cellular interpretations of Ribo-seq ORF translations. Below, we list several of the most likely 
possibilities. Note that a given ORF may encompass several of these possibilities, e.g., a translated ORF that is both 
regulatory and implicated in disease neoantigen production. 
 
1. A Ribo-seq ORF encodes a ‘missing’ conserved protein. Such ORFs can be recognised as canonical – in 
accordance with existing protein annotations – on the basis that the sequence of the protein they encode shows 
clear evidence of being maintained by evolutionary selection over a significant period of evolutionary time (Magny 
et al., 2013; Pauli et al., 2014). 
 
2. A Ribo-seq ORF encodes a taxonomically restricted protein. Such ORFs encode proteins whose sequence 
and molecular activities are specific to one species or lineage. Evidence for selection or conservation across 
distant species or lineages is lacking for these ORFs, either because the protein sequence has diverged beyond 
recognition from its orthologues, or because the protein evolved recently from previously noncoding material and 
homologues do not exist in other species or lineages (Vakirlis et al., 2020a). 
 
3. A Ribo-seq ORF regulates protein or RNA expression. Translation of regulatory ORFs does not result in a 
protein product under selection but regulates the expression of a canonical protein. This paradigm is well 
established for uORFs and uoORFs, as noted in Box 1, though it is potentially applicable to other transcript 
scenarios. Regulatory ORFs may compete for ribosomes with their downstream canonical ORFs or produce 
nascent peptides that stall ribosomes (Lovett and Rogers, 1996), leading to the controlled „dampening‟ of protein 
expression (Johnstone et al., 2016). Alternative modes of action, such as the induction of RNA decay pathways, 
the processing of small RNA precursors or the adjustment of RNA stability, have also been inferred (Carlevaro-
Fita et al., 2016; Sun et al., 2020; Tani et al., 2013). 
 
4. A Ribo-seq ORF is the result of random  translation. The translation of some Ribo-seq ORFs may simply be 
„noise‟. Since translation has a high bioenergetic cost (Lynch and Marinov, 2015), a protein that results from 
random translation is likely to be translated at lower levels than a canonical CDS and evolve neutrally (Ruiz-
Orera et al., 2018); it may also be unstable in comparison, and be potentially rapidly degraded. Nonetheless, it is 
theoretically possible that certain proteins do exist as stable „junk‟ proteins, or that random translation events 
affect the expression of the canonical protein. The detection of random ORFs is less likely to be reproducible.  
 
5.  A Ribo-seq ORF translates a disease-specific protein. This protein would not be produced under normal 
physiological homeostasis but could be of major interest for diagnostics and therapeutics. Insights are especially 
emerging in cancer biology, where transcription and translation are known to be dysregulated. This leads to the 
production of „aberrant‟, possibly rapidly-degraded proteins that are commonly antigenic and presented on the 
cell surface by the HLA system, offering the prospect of neoantigens (Chong et al., 2020; Laumont et al., 2016, 
2018; Ouspenskaia et al., 2020; Ruiz Cuevas et al., 2021). In addition, antigens resulting from disease-specific 
dysregulated ribosome activity - sometimes called defective ribosomal products (DRiPs) (Rock et al., 2014; 
Yewdell et al., 1996) - have also been explored. 
 
.CC-BY-NC-ND 4.0 International licenseavailable under a
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made 
The copyright holder for this preprintthis version posted June 10, 2021. ; https://doi.org/10.1101/2021.06.10.447896doi: bioRxiv preprint 
7 
 
A community-driven approach to Ribo-seq ORF 
annotation 
The increasing trove of Ribo-seq data and the growing 
community interest in newly detected Ribo-seq ORFs have 
„forced‟ the issue of their annotation. It is clear that Ribo-seq 
datasets do contain insights of great value for genome 
annotation. To this end, the GENCODE gene annotation 
project recently convened a broad panel of experts in the 
field of RNA translation, ribosome profiling, noncoding RNA 
biology and ORF detection, in order to begin this work in a 
„community-led‟ manner. The major goals of this effort are: 
(1) to ensure appropriate technical analysis and 
incorporation of existing Ribo-seq datasets; (2) to establish a 
consensus strategy for the biological interpretation of Ribo-
seq data; (3) to convert this into a systematic framework for 
gene annotation that is appropriate for wide-ranging public 
use.  
    For the research community, this work seeks to solve 
several existing problems. Primarily, current efforts to find 
ORFs lack coordination. Although the field is in its infancy, it 
is clear that ORF collections provided by research 
publications often have significant overlaps. We anticipate 
that groups will continue to „rediscover‟ ORFs that have 
already been reported while there remains no „consensus‟ 
ORF catalog with widespread buy-in from the research 
community; existing databases such as sORFs.org (Olexiouk 
et al., 2018), OpenProt (Brunet et al., 2019) and the uORF 
catalog produced by McGillivray et al (McGillivray et al., 
2018) employ disparate parameters not agreed upon at the 
community level, and these catalogues are not embedded in 
the gene annotation „ecosystem‟. 
    To this point, it is clear that representation in reference 
annotation databases maximises visibility, and the 
importance of this cannot be overstated. Pertinently, there 
are numerous examples of ORFs that have been 
investigated independently and in great detail by multiple 
research groups. For example, LINC00116 was first reported 
to produce a 56 amino acids protein in 2013 (Catherman et 
al., 2013). Subsequently, a series of publications assigned 
different names to this protein including MTLN (Chugunova 
et al., 2019; Stein et al., 2018), MOXI (Makarewich et al., 
2018), MPM (Lin et al., 2019), and LEMP (Wang et al., 2020) 
(it is now officially named as protein-coding gene MTLN). 
Another lncRNA example is the murine Gm7325, shown to 
encode an 84 amino acids protein termed Myomixer (Bi et 
al., 2017), Myomerger (Quinn et al., 2017) or Minion (Zhang 
et al., 2017), since named as „myomixer, myoblast fusion 
factor‟ (MYMX) in humans. While some of this research may 
have overlapped in time, the usage of disparate names may 
engender confusion amongst researchers. Protein-coding 
ORFs within the 5‟ UTRs (uORFs) of SLC35A4 (Andreev et 
al., 2015), MIEF1 (Andreev et al., 2015; Brown et al., 2017; 
Delcourt et al., 2018; Rathore et al., 2018), ASNSD1 
(Cloutier et al., 2020), and MKKS (Akimoto et al., 2013) have 
also been detected and characterized. These four uORFs 
are now annotated as protein-coding by GENCODE and 
named by HGNC, and should no longer be reported as 
„novel‟ by studies that compare against the latest gene 
annotations. Moving forward, we anticipate that, if a 
centralised ORF collection can be agreed upon by the 
research and annotation communities, then this will help the 
field move beyond the initial ORF „discovery‟ phase into 
placing the emphasis on experimental characterisation.  
  
Devising a framework for the annotation of Ribo-seq 
ORFs 
The process to incorporate human Ribo-seq ORFs into 
reference genome annotations is anticipated to occur in two 
phases. The first phase (Phase I) involves the creation of a 
consolidated list of literature-reported Ribo-seq ORFs 
(Calviello et al., 2016; Chen et al., 2020; Gaertner et al., 
2020; van Heesch et al., 2019; Ji et al., 2015; Martinez et al., 
2019; Raj et al., 2016) that have been matched to 
GENCODE annotations (Supplementary Tables S1-3). 
Literature sources for human ORFs were selected based on 
the comprehensiveness of the dataset, specific focus on 
large-scale ORF detection, and transparency in reporting 
multiple categories of detected ORFs in the available 
supplementary files. Thus, although additional human Ribo-
seq datasets have been published that do not focus on ORF 
detection, for the Phase I catalog we have not reanalyzed 
these data. Our efforts here are restricted to collating 
previously not annotated ORFs from studies that used their 
own experimental and computational workflows for ORF 
detection. Furthermore, computational studies that identified 
ORFs from Ribo-seq datasets already used by others for 
ORF detection were excluded to avoid redundancy in 
reporting ORFs from the same source data twice. This 
Phase I catalog of ORFs has been released with this article 
(see below for discussion and Supplementary Files). We 
recognise that the relative paucity of Ribo-seq data across 
many human tissues and cell lines prohibits a biologically 
comprehensive list of human Ribo-seq ORFs at this time. As 
this field has only emerged recently, there is currently no 
standard, widely accepted approach to identify Ribo-seq 
ORFs. For instance, among the seven datasets selected for 
inclusion in Phase I, there are various ORF discovery 
pipelines, reference annotations and human genome builds 
used. Following this, we anticipate a second phase (Phase 
II; see below) that aims for deeper ORF integration into the 
GENCODE gene annotation and the wider resources of the 
Ensembl database. In the intervening period, it will be 
possible to update the Phase I catalog as more Ribo-seq 
datasets are published and gene annotations continue to 
expand. 
    To achieve standardization, we defined a set of 8,805 
unique Ribo-seq ORF sequences identified within the above-
listed seven studies, each of which were fully mapped to 
Ensembl Release v.101 (August 2020, equivalent to 
GENCODE v37, see Methods and Figure 2A) on genome 
assembly GRCh38. Because the selected studies applied 
different minimum ORF length cut-offs and were inconsistent 
in their reporting of near-cognate ORFs - ORFs employing a 
leucine or valine initiation codon rather than methionine - we 
only included cognate Ribo-seq ORFs that were 16 amino 
acids or longer. Considerations regarding ORF length and 
near-cognate ORFs are discussed below. Next, we 
discarded Ribo-seq ORFs that had already been newly 
annotated as protein-coding or pseudogene in the 
GENCODE v37 update, as well as any in-frame variations to 
existing protein-coding isoforms (Figure 2A, Supplementary 
Table S4). In order to mitigate redundancy in Ribo-seq ORF 
calls, we collapsed instances of multiple isoforms of the 
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Figure 2: Characterization of a consensus set of Ribo-seq ORFs for annotation by GENCODE. (A) A schematic overview of filtration of 
candidate ribosome profiling (Ribo-seq) ORFs employed in this work. The final consensus list of Ribo-seq ORFs for Phase I includes 7,264 
cases. (B) A pie chart showing the abundance of ORFs filtered out in each step of the pipeline. (C) A diagrammatic representation of all Ribo-
seq ORFs (left) and a subset of replicated Ribo-seq ORFs (right) according to ORF type. (D) Replication of Ribo-seq ORFs in lncRNAs (left) 
and in mRNAs (right) within each Ribo-seq dataset employed. (E) Bar plots with abundances of replicated and non-replicated ORFs across 
each dataset. Cumulative lines illustrate the evolution in the total number of new unique ORFs identified across studies, sorted chronologically. 
ORFs are plotted separately for clarity. (F) The nucleotide sequence length of replicated Ribo-seq ORFs compared to annotated CDSs 
(aCDS). ORFs are separated into each respective class. Ribo-seq ORFs are significantly shorter than annotated CDS (two-sided Wilcoxon 
test, p-value < 10
-10
) (G) The phyloCSF scores assessing amino acid purifying selection for ORFs compared to annotated CDSs less than 100 
amino acids in length (short CDS, sCDS). Only 2.4% of the replicated Ribo-seq ORFs displayed positive PhyloCSF scores, in contrast to 48% 
of the sCDS. 
 
 
same ORF when they shared ≥ 90% of the amino acid 
sequence, selecting the longest ORF as representative. In 
total, across all seven datasets, this results in the annotation 
and inclusion of 7,264 unique cognate ORFs detected in at 
least one dataset (Figure 2A-C, Supplementary Tables S2 
and S3). 
 
How reproducible are Ribo-seq ORF identifications? 
One barrier for GENCODE in assembling a usable Ribo-seq 
ORF dataset is the variability in ORF identifications. In light 
of this, one approach to gain confidence in Ribo-seq data is 
to evaluate how frequently the same ORF is identified across 
independent studies. This approach has significant technical 
considerations, due to the fact that the existing studies 
employ various protocol variations and computational 
pipelines to process Ribo-seq data. These computational 
methods (including but not limited to RibORF (Ji et al., 
2015), ORF-RATER (Fields et al., 2015) and RiboTaper 
(Calviello et al., 2016)) can identify ORFs with significant 
frame preference by additionally evaluating distinct features 
that reflect the dynamics of translation initiation, elongation 
and termination (Calviello and Ohler, 2017). For the 
purposes of Phase I, we have used the existing Ribo-seq 
ORF calls reported in the original manuscript, and we have 
focused on the list of Ribo-seq ORFs found by more than 
one dataset as an indicator of robustness of the Ribo-seq 
signal and low chance that such ORFs reflect spurious 
variations in data processing methods. These were called 
“replicated” ORFs (Figure 2B-E, Supplementary Table S2). 
In total, we identified 3,085 replicated ORFs: 668 ORFs from 
annotated lncRNAs (30.1% of all identified lncRNA-ORFs), 
1,767 uORFs (57.3% of all uORFs), 432 overlapping uORFs 
(62.8% of all uoORFs), 115 downstream ORFs (12.8% of all 
dORFs), 5 downstream overlapping ORFs (8.2% of all 
doORFs) and 98 internal out-of-frame ORFs (13.6% of all 
intORFs). Consistent with known features of Ribo-seq ORFs, 
this set of replicated ORFs was significantly smaller in size 
compared to annotated CDSs and presented lower 
PhyloCSF scores - i.e. demonstrated less evidence for 
evolution as protein-coding sequences - compared to 
annotated CDSs of a similar small size (Figure 2F,G). 
    It is important to note that reproducibility of these 3,085 
replicated ORFs demonstrates consistency in the Ribo-seq 
signal, but it does not confirm that an ORF has a biological 
role nor provides insights into what its function may be. 
Conversely, this selection process does not indicate that the 
4,179 ORFs not replicated across multiple studies are 
“false”. Indeed, Ribo-seq analyses in human cell types 
remain fairly limited. Since transcription is commonly 
restricted depending on tissue or cell type, especially for 
evolutionarily recent genes, we would expect a similar 
pattern for translation of ORFs encoded by these genes. 
Moreover, dozens of ORFs are only translated during 
specific biological processes, such as cell stress (Ramilowski 
et al., 2020; Starck et al., 2016). Thus, for example, the 
dataset from van Heesch et al is taken only from heart (van 
Heesch et al., 2019), while none of the other studies include 
this tissue, and therefore a prejudicial view against any 
ORFs found in this study alone would be unjustified.  
 
Consideration of Ribo-seq ORF length  
To our knowledge, there is no specific size threshold at 
which an oligopeptide sequence gains the capacity to be a 
bona fide protein, and reference annotation projects do not 
have minimal size criteria for protein sequences. Protein 
secondary structure is thought to be possible at 
approximately 14 amino acids (Imura et al., 2014) for alpha 
helices and potentially even less for other secondary 
structure formations (Kumar and Kishore, 2010), although it 
is known that some protein sequences are unstructured 
(Dyson et al., 2005). Even before the advent of Ribo-seq, 
small proteins had been well characterized in numerous 
organisms. For example, tarsal-less (tal) gene, also named 
mille-pattes (mlpt) or polished-rice (pri), produces a 
polycistronic transcript translated into proteins as short as 11 
amino acids in several insect species, such as Drosophila 
melanogaster (Galindo et al., 2007) and Tribolium 
castaneum (Savard et al., 2006). In humans, SLN encodes a 
muscle-specific 31 amino acid protein known to interact with 
several Ca(2+)-ATPases reducing the accumulation of 
Ca(2+) in the sarcoplasmic reticulum (Bal et al., 2012), and 
this protein has homology extending to fly genomes (Magny 
et al., 2013). Small proteins may also be medically-important 
targets: the CD52 gene encodes a cell surface antigen that 
is only 61 amino acids but is clinically actionable via the 
monoclonal antibody alemtuzumab, which has been FDA-
approved since 2001 (Dumont, 2001). With the assistance of 
Ribo-seq and computational approaches such as PhyloCSF, 
highly conserved human proteins as short as 25 amino acids 
have already been discovered and annotated prior to our 
work here (Anderson et al., 2015; Mudge et al., 2019; Pauli 
et al., 2014). Among the smallest known human protein 
products are the enkephalin neuropeptides, which are just 5 
amino acids in length (Gayen and Mukhopadhyay, 2008; 
Marcotte et al., 2004), although these are produced by 
proteolytic cleavage from a larger precursor protein. Among 
Ribo-seq ORFs, there is limited evidence that even small 
ORFs can serve as regulatory elements (e.g., ATF4 uORF1 
is 3 amino acids long (Vattem and Wek, 2004), and AMD1 
uORF is 6 amino acids long (Ruan et al., 1996)).  
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    For the purposes of this effort, we have considered ORFs 
that are at least 16 amino acids in length. Our threshold is 
largely a practical one, as the literature studies from which 
we derive our Phase I ORFs are inconsistent in their 
reporting of ORFs smaller than this threshold. Moreover, 
while peptides derived from proteolytic cleavage may have 
physiologic roles in some contexts, the process of vetting 
very small ORFs from Ribo-seq data becomes increasing 
complicated as computational methods for Ribo-seq data 
may nominate very short ORFs with variable fidelity, and 
such ORFs may be too small for unambiguous detection by 
mass spectrometry due to limitations in aligning MS peptides 
of very small size. Nevertheless, we recognize that ORFs < 
16 amino acids are numerous in Ribo-seq data (Figure 1B) 
and some of them can be replicated in more than one Ribo-
Seq dataset (Supplementary Table S5), which may prove to 
be an important area for ongoing investigation and an 
opportunity for GENCODE to be more inclusive in terms of 
minimal ORF sizes in the future. 
 
Near-cognate initiation codons among Ribo-seq ORFs 
While the translation of ORFs using an AUG cognate 
initiation codon is the most frequent and efficient (Kearse 
and Wilusz, 2017; Kolitz et al., 2009), other near-cognate 
codons can initiate translation in specific sequence contexts 
(Diaz de Arce et al., 2018). Generally, CUG is the most 
efficient near-cognate start codon followed by GUG (Kearse 
and Wilusz, 2017). One prominent example is the MYC 
oncogene, which has a well-established CUG start site used 
in some contexts (Hann et al., 1988), though no obvious 
phenotypic consequences of this alternative protein product 
have yet been reported (Blackwood et al., 1994). 
Computational prediction of near-cognate translational 
initiation sites (TISs) does not always result in unambiguous 
identification of TIS positions (Lee et al., 2012). Ribo-seq 
following lactimidomycin or homoharringtonine treatment can 
be used to accurately identify TISs; these drugs inhibit 
translation elongation (Ingolia et al., 2011; Lee et al., 2012) 
and so result in accumulation of Ribo-seq reads at the 
putative TIS.  
    Only four of the seven selected ORF datasets reported 
near-cognate ORFs, limiting our ability to assess their 
replicability across studies. As such, we have elected to 
exclude them from the initial Phase I release, though future 
ORF annotation releases may elect to incorporate them as 
more data becomes available. For the purposes of this 
manuscript, we have enumerated the abundance of near-
cognate ORFs available in the four datasets reporting them. 
These studies identified a total 10,412 unique near-cognate 
ORFs, which we remapped to Ensembl v.101, with CUG 
(49%) and GUG (19%) being the most frequent non-AUG 
TISs, as also reported by other Ribo-seq studies (Fritsch et 
al., 2012; Lee et al., 2012). For several specific cases, we 
observed near-cognate ORFs that have a strong 
trinucleotide periodicity signal, do not contain any nearby 
AUG codon upstream or downstream of the TIS, and are 
replicated across studies. For instance, BPNT2 uORF starts 
with CUG and translates a small ORF of 36 amino acids 
(Figure 3A). However, for ~17% of the near-cognate ORFs, 
other studies reported a different overlapping translation 
starting with AUG (e.g., ANKRA2 uORF; Figure 3B), or even 
different ORFs starting with a mix of alternative near-cognate  
 
 
Figure 3: Near-cognate ORFs with consistent or inconsistent 
Ribo-seq nominations. (A) A uORF located in the BPNT2 gene 
has multiple datasets supporting translation at a near-cognate 
initiation codon. (B) A uORF located in the ANKRA2 gene has a 
near-cognate initiation codon but also a separate annotation utilizing 
a methionine initiation codon. (C) A Ribo-seq ORF located in the 
ZBTB11-AS1 lncRNA has several proposed initiation codons 




and AUG codons (e.g. ZBTB11-AS1 lncRNA-ORF; Figure 
3C). Such ORFs may participate in cell biology: in the case 
of ZBTB11-AS1 ORF, recent experimental data has now 
contextualized a role in maintenance of cell survival 
(Prensner et al., 2021). In addition, only ~6% of the near-
cognate Ribo-seq ORFs could be replicated in at least 2 of 
the analyzed Ribo-seq datasets, illustrating the challenge of 
accurately predicting near-cognate TISs and ORFs in these 
experiments. 
 
Conserved protein-coding genes within the Ribo-seq 
ORF catalog 
Ribo-seq ORFs will require detailed, multifaceted 
approaches to elucidate their biological roles, and a core 
goal of this work will be to find those that encode bona fide 
proteins. It is clear that evolutionary metrics cannot be the 
sole arbitrators of biological function in this regard. 
Experimental evidence will be especially important for those 
lineage-specific ORFs that emerged de novo, where their 
activity at the protein level cannot be inferred by 
conservation and CDS constraint, and these metrics may be 
of little value in the study of neo-epitope antigenicity 
(Laumont et al., 2016, 2018). In a broader context, a myopic 
focus on protein evolution could also hold back the study of 
Ribo-seq ORFs that do not impart function at the protein 
level. This would seem to be especially problematic given 
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the recent insight that purifying selection is widespread 
across AUG codons initiating uORFs in eukaryotes (Zhang 
et al., 2021). 
    Nonetheless, we believe that evolutionary analyses still 
have a major role to play in Ribo-seq ORF research. Given 
that the human genome has been vigorously and repeatedly 
surveyed for missing proteins according to evolutionary 
profiling in recent years, we might anticipate that very few 
Ribo-seq ORFs encode ancient proteins. However, as noted, 
it may be hard to interpret evolutionary signatures in very 
small CDSs - especially to distinguish CDS constraint from 
DNA conservation - and so it could be that small proteins 
commonly „fly under the radar‟, especially in studies that 
employ minimal length criteria. Furthermore, we currently 
lack detailed knowledge as to how algorithms such as 
PhyloCSF will perform in the identification of dual frame 
translations, although the protein-coding uoORF recently 
discovered in POLG was able to be identified in this way 
(Khan et al., 2020). Moreover, a modest number of 
replicated Ribo-seq ORFs in the datafile do show positive 
PhyloCSF signals (75 out of 3,085 ORFs; 2.4%), potentially 




Figure 4: Ribo-seq ORFs in HR and ATXN1 now considered as 
protein-coding sequences by GENCODE. (A) A 34 amino acid 
uORF (green box) identified within the 5‟ UTR of HR (UTR 
sequences in grey boxes; CDS in purple boxes) has been annotated 
as protein-coding (ENSG00000288677), now recognised as HRURF 
by HGNC. The protein-coding nature of the ORF was inferred by 
PhyloCSF, according to the positive signal in the top reading frame. 
Further support was provided by in depth comparative annotation of 
other vertebrate genomes, demonstrating that the protein likely 
evolved at the base of the therian mammal radiation; an illustrative 
alignment is included („Plat‟ standing for platypus). HR has an 
ortholog in avians and reptiles; the equivalent sequence in these 
genomes lacks coding potential (not shown), indicating that HRURF 
evolved de novo. Five ClinVar variants fall within HRURF: 
RCV000007766.4, RCV001030440.1, RCV000007767.4, 
RCV000007768.4 and RCV000007769.3 in 5‟ order. Each is 
classed as „Pathogenic‟, although non-coding. Following the new 
CDS annotation, mutations RCV000007766.4 and RCV001030440.1 
are seen to disrupt the initiation codon, RCV000007767.4 and 
RCV000007768.4 are missense mutations, while RCV000007769.3 
disrupts the termination codon. (B) A 29 amino acid uORF within the 
complex 5‟ UTR of ATXN1 has been annotated as protein-coding, 
and will appear in a future GENCODE release. This translation has 
been evolving as coding sequence across the vertebrate radiation 
(„Chick‟ is chicken, „Xen‟ is Xenopus, „Zebf‟ is zebrafish), and the 
strong PhyloCSF signal (not shown) produced a PhyloCSF 
Candidate Coding Region (red triangle), indicative of a non-
annotated CDS. The canonical transcript of ATXN1 
(ENST00000244769, top model) has six additional 5‟ UTR exons 
with three uORFs inferred from the Ribo-seq datafile (the 17 amino 
acid and 45 amino acid ORFs are overlapping in different reading 
frames), while a final ORF has been mapped to an alternatively 
spliced non-coding transcript (ENST00000467008, second model). 
While these various UTR exons are generally conserved and 
supported by transcript evidence in other mammal genomes, the 
additional ORFs are not strongly conserved and do not present 
signatures of purifying selection as CDS. 





    We have now manually analysed each of these Ribo-seq 
ORFs according to standard GENCODE annotation criteria, 
which includes in depth comparative annotation. In total, 10 
Ribo-seq ORFs in the datafile have now been annotated as 
protein coding by GENCODE, as detailed in Supplementary 
Table S6. For clarity, this file lists 15 additional ORFs that 
have become protein coding in GENCODE within the last 
two years, following parallel or integrated PhyloCSF and 
Ribo-seq analyses that predate our current efforts 
(unpublished data). These annotation decisions have been 
made unilaterally by GENCODE largely based on the 
interpretation of PhyloCSF, which demonstrates protein 
evolution but not protein function, and it will be important to 
study these translations with additional experimental 
approaches. We note that the criteria for classifying a 
protein-coding gene in reference annotation projects does 
not require certainty in coding status, simply the 
consideration that this is the most likely explanation of the 
body of evidence. Furthermore, we do not claim to have 
identified all conserved proteins in the datafile, and the 
evolutionary provenance of many Phase I ORFs remains 
hard to interpret.  
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    We highlight two cases in Figure 4. Firstly, a Ribo-seq 
ORF (HRURF) identified within the 5‟ UTR of the HR lysine 
demethylase and nuclear receptor corepressor (HR) has 
been evolving as a protein since at least the base of the 
mammal radiation (Figure 4A). This CDS contains 5 
pathogenic „non-coding‟ ClinVar mutations linked to genetic 
hair-loss phenotypes that can now be reappraised as 
missense or loss-of-function protein-coding mutations. These 
variants were originally noted in a study that identified the 
ORF but considered it to be a potential regulatory element 
(Wen et al., 2009); the protein-coding nature of the ORF was 
not established in annotation catalogs until now. Secondly, 
we have annotated a Ribo-seq uORF within the highly 
complex 5‟ UTR of ataxin 1 (ATXN1) as encoding a protein 
which is conserved in vertebrate genomes (Figure 4B). This 
is one of five distinct Ribo-seq ORFs from our dataset that 
are found within the 5‟ UTR of this gene; the other four 
exhibit varying degrees of sequence conservation, although 
they lack PhyloCSF support for CDS evolution. Interestingly, 
a nested ORF within the canonical ATXN1 CDS was 
previously shown to be translated as a stable protein 
(Bergeron et al., 2013). Further experimental work will be 
required to decipher the apparently complex mechanisms of 
this locus, which is linked to cerebellar ataxias, and recent 
research indicates that translational control is at least in part 
mediated by alternative splicing in the 5‟ UTR (Manek et al., 
2020).  
 
A resource for Ribo-seq ORFs 
Apart from the 10 conserved protein-coding ORFs described 
in the previous section, GENCODE have not yet integrated 
Ribo-seq ORFs into the existing „data models‟ for human 
protein-coding or lncRNA genes, but present them as a 
separate datafile in the GENCODE portfolio. These 
annotations are „hygienically‟ isolated from the other aspects 
of the Ensembl resources in order to avoid their 
unsupervised propagation into downstream projects; users 
will be able to make the active decision to incorporate them. 
This does not reflect a general lack of confidence in their 
potential biological importance, rather our current inability to 
annotate different modes of ORF function (Box 2). In 
particular, we wish to avoid numerous Ribo-seq ORFs 
suddenly being included in analyses intended only for 
validated human protein-coding exons, such as germline or 
somatic variant calling. The future incorporation of Ribo-seq 
ORF annotations in the main annotation will require solutions 
to complex problems in database structure. Many Ribo-seq 
ORFs are identified on existing mRNA transcripts, i.e. 
uORFs, uoORFs, dORFs, doORFs and intORFs. Yet it is 
largely unclear if these scenarios reflect truly polycistronic 
mRNA translation akin to the polycistronic translation of 
unique, independently translated proteins observed in viral 
genomes, and the situation is further complicated by our  
understanding that translations may instead have a 
regulatory mode. While it is well established that alternative 
ORFs on mRNAs can be translated to the latter effect, more 
information is needed on the potential of the human genome 
to produce transcripts expressing multiple independent 
proteins from the same molecule. It could be that distinct 
proteins are accessed by other mechanisms including 
alternative transcription. The answers to these questions will 
have significant practical implications, including in the 
interpretation of genomic variation. For example, it could be 
that a given promoter mutation affects the transcription 
and/or translation of only one of the ORFs. Alternatively, a 
mutation may affect both ORFs; variants that dampen uORF 
translation may increase translation of the downstream 
protein, and conversely variants that increase uORF 
translation - including gain of function variants that create 
new uORFs - may dampen downstream translation (Whiffin 
et al., 2020). 
    A related question is whether protein-coding Ribo-seq 
ORFs that are found within the same locus as a known 
protein - e.g. those in the 5‟ UTRs of HR and ATXN1 (Figure 
4A,B) - should be considered as separate genes. This is not 
a mere semantic argument. From the biological perspective, 
there is evidence that some 5‟ UTR proteins interact with the 
downstream known protein (Chen et al., 2020). On the other 
hand, in several well-studied cases such as the MKKS locus 
(Akimoto et al., 2013) the identified functions of the upstream 
and downstream proteins appear to be totally distinct. This 
question is of core importance in reference gene annotation, 
especially because many users - and in particular large 
clinical projects - commonly choose to work with one or few 
transcript models per gene. The „visibility‟ of protein-coding 
Ribo-seq ORF annotations is likely to be severely impacted 
by such approaches if they are merged into the annotation 
for the known protein, as these short proteins will be at 
significant risk of being filtered out. For these pragmatic 
reasons, moving forward, GENCODE, UniProt and HGNC 
have therefore agreed to annotate protein-coding uORFs, 
ouORFs, intORFs, doORFs and dORFs as novel genes that 
are distinct from the known protein at the same locus.  
    GENCODE decided to be largely agnostic in the Phase I 
ORF catalog, avoiding claims about which ORFs appear 
more likely to be biologically or medically important, or how 
they may act. There is little experimental characterization 
available for most Phase I Ribo-seq ORFs, and it is hard to 
predict which ones will gain additional experimental 
validation in the future. Therefore, we do not separate ORFs 
into different „biotypes‟ (i.e., protein-coding vs. regulatory, 
etc) as this would be largely speculative at the present time. 
Instead, we categorize them according to the same schema 
used in Box 1 (i.e. uORF, lncRNA-ORF etc). While these 
specific terms are suitable for our purposes as we develop a 
unified annotation framework, their usage here is preliminary 
and does not reflect the development of a finalised 
classification system.  
    We recognize the utility of MS in identifying peptide-level 
evidence for those Ribo-seq ORFs that produce stable 
proteins. However, MS presents its own set of challenges, 
and there is significant debate on whether or how MS 
methods should be modified to enhance the detection of 
small ORFs (Chen et al., 2020; Na et al., 2018; Ouspenskaia 
et al., 2020; Oyama et al., 2004). At the present time there is 
little consistency between different studies regarding MS 
data generation and analysis for orthogonal validation of 
Ribo-seq ORFs. For Phase I, we therefore decided to record 
whether an MS peptide was uniquely identified for a given 
ORF in its metadata based on the analysis performed in the 
original study, collecting proposed evidence for 424 
replicated Ribo-seq ORFs (Calviello et al., 2016; Cao et al., 
2020; Chong et al., 2020; Granados et al., 2014; van Heesch 
et al., 2019; Kim et al., 2014; Laumont et al., 2016, 2018; Ma 
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et al., 2014, 2016; Martinez et al., 2019; Prensner et al., 
2021; Raj et al., 2016; Slavoff et al., 2013; Vanderperre et 
al., 2013; Zhu et al., 2018) (Supplementary Tables S2 and 
S7). This approach presents the reported data to the user at 
face value. In the future, Phase II will address the topic of 
mass spectrometry for Ribo-seq ORFs in greater detail. 
    In summary, our intention is for the ORF catalog produced 
by Phase I of this project to be seen not as the final answer 
to a problem, rather as a pragmatic interim solution. Moving 
forward, we will track changes to the Ribo-seq ORF 
annotations on the GENCODE webportal, and will provide 
updated versions of the datafile. The annotation of Ribo-seq 
ORFs considered to be protein-coding will be coordinated 
between GENCODE, UniProt and HGNC, and also 
performed in collaboration with RefSeq. Above all, we 
anticipate that this initial support for Ribo-seq ORFs by 
reference gene annotation projects will be of benefit to both 
the research groups discovering and characterising these 
ORFs, as well as to the broad user community of these 
biological databases.  
  
Future perspectives 
The recognition of unannotated translation through Ribo-seq 
data has upended concepts about the translational capacity 
of the human genome. These data lead to many important 
questions: How many Ribo-seq ORFs represent canonical 
protein-coding regions, encoding biologically active protein 
products? How many Ribo-seq ORFs impart gene regulation 
through the act of their translation? How do Ribo-seq ORFs 
arise and to what extent are recently evolved ORFs under 
selection? What proportion of transcriptional and 
translational processes that occur in the cell make a minimal 
contribution to phenotype and fitness? What are the specific 
implications for Ribo-Seq ORFs in human genetic diversity, 
health and disease? Will the answers to these questions 
challenge our definition of a gene, and the current 
categorical biotyping system employed for gene annotation? 
    In our view, answering these questions will not be easy, 
and it is clear that this will not be a short-term endeavour. 
Furthermore, the development of new biological paradigms 
will depend on the integration of broad experimental 
research alongside new analytical methodologies. Already, 
there have been increasing efforts to dissect the relevance of 
Ribo-seq ORFs using high-throughput techniques (Chen et 
al., 2020; Liang et al., 2016; Prensner et al., 2021), genome-
wide correlative studies (Calvo et al., 2009; Chew et al., 
2016), and individual experimental investigations in diverse 
contexts (Anderson et al., 2015; Bi et al., 2017; Huang et al., 
2021; Pauli et al., 2014). We anticipate that future studies 
along these lines will allow for further refinement of the ORF 
catalog, and gene annotations more generally. For example, 
independently of our work, a 46 amino acid Ribo-seq ORF 
from our catalog found within the 5‟ UTR of ZNF689 has 
recently been experimentally validated as a bona fide 
protein, with a prospective trans role in transcriptional 
regulation (Koh et al., 2021).  
    We also recognize that ongoing Ribo-seq ORF research in 
other species has the potential to address questions on the 
evolution of translation, as well as to provide model systems 
for the experimental investigation of both conserved ORFs 
and species-specific non-human ORFs (e.g., knock-out 
mouse models were recently used to investigate a 
conserved protein-coding uORF in the PTEN gene (Huang et 
al., 2021) and a rodent-specific ORF in the lncRNA 
AW112010 (Jackson et al., 2018)). Our roadmap for human 
Ribo-seq ORF annotation may also provide guiding 
principles for Ribo-seq ORF incorporation as part of other 
species annotation projects 
    Ribo-seq ORFs continue to provoke conversations about 
gene birth (Keeling et al., 2019; Ruiz-Orera and Albà, 2019a; 
Ruiz-Orera et al., 2015) and they have opened new vistas for 
the study of human variation in disease (Whiffin et al., 2020), 
including variants in these ORFs that may cause human 
disease phenotypes (Schulz et al., 2018; Wen et al., 2009; 
Whiffin et al., 2020). It may ultimately be that a significant 
number of Ribo-seq ORFs prove to be relevant in human 
health and disease. In light of this, reference annotation 
databases have the unique capacity to advance this line of 
research through the propagation and standardization of 
Ribo-seq ORF datasets, even - and perhaps especially - 
while the phenotypic impact of these features remains 
largely uncertain. Establishing a central database of Ribo-
seq ORFs will enable greater coordination, consistency and 
accessibility for researchers globally. Integration of 
GENCODE efforts with other authoritative resources such as 
UniProt and RefSeq will further advance these efforts. We 
envision that the long-term effects of such efforts will yield 
substantial insight in a key area emerging in human biology. 
    In this spirit, we hope the results of Phase I of this project 
- as well as our views and considerations on the 
interpretation and annotation of Ribo-seq ORFs - will be 
useful and beneficial to the community. We also invite 
interested labs to reach out and join our future efforts toward 
the further evaluation and integration of Ribo-seq datasets 
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All analyses in this study are performed using published and 
publicly available analytical tools or software packages. 
Published Ribo-seq ORF datasets and processed mass-
spectrometry peptide datasets were retrieved from the 
Supplementary Material of each referenced study as 
described in Supplementary Tables S1 and S7. The code 
used for generating the list of Phase I ORFs is available at 
https://github.com/jorruior/gencode-riboseqORFs.  
 
Supplementary File 1: 
 
Table S1. Description of the 7 human Ribo-seq datasets 
used for this study 
Table S2. Table with 3,085 replicated Ribo-seq ORFs that 
were found in at least two Ribo-seq studies. LncRNA-ORFs 
were divided into two categories (see ORF biotype): lncRNA 
(lncRNA-ORFs in lncRNA genes) and processed_transcript 
(lncRNA-ORFs in protein-coding genes) 
Table S3. Table with 4,179 Ribo-seq ORFs that are from a 
specific Ribo-seq study. LncRNA-ORFs were divided into 
two categories (see ORF biotype): lncRNA (lncRNA-ORFs in 
lncRNA genes) and processed_transcript (lncRNA-ORFs in 
protein-coding genes) 
Table S4. Table with 957 Ribo-seq ORFs currently 
annotated as protein-coding (CDS or NMD) or overlapping 
pseudogenes in Ensembl v.101. ORFs partially or totally 
overlapping in-frame CDS were included in this table. If two 
or more ORFs shared >= 90% of the amino acid sequence, 
only the longest one was included. 
Table S5. Table with 1,520 Ribo-seq ORF sequences 
discarded due to the short size (< 16 amino acids). These 
ORFs were replicated in at least two Ribo-seq studies. 
Table S6. This sheet lists 10 ORFs that have been 
annotated as protein-coding by GENCODE as part of this 
work, and a further 15 that were previously annotated as part 
of preliminary investigative work into Ribo-seq datasets 
combined with in-house PhyloCSF analysis. Proteins that 
are listed as appearing in GENCODE v38-39 are not in a 
public „genebuild‟ release at the time of publication, and so 
gene and transcript IDs are not yet available for these 
models. Note that while the „comments‟ provide brief 
explanations for the annotation, they do not attempt to 
establish provenance for the initial identification of the ORF 
or protein. Further support for these annotations could 
potentially be found in additional resources or publications. 
These annotation decisions were made by GENCODE 
according to an interpretation of the balance of probability 
when considering all available evidence, i.e. these ORFs are 
considered most likely to be protein-coding, in line with 
standard annotation criteria. GENCODE recognise that 
further experimental characterization will be required to 
support these annotations.  
Table S7. Description of the 16 mass-spectrometry datasets 
used for this study. Identified peptides were retrieved from 
supplementary data and re-mapped to Ribo-seq ORFs. 
Table S8. Table with 80 Ribo-seq ORF sequences that could 
not be mapped to any of the current transcript annotations in 
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Phase I ORF retrieval and mapping 
We selected seven ORF datasets from different human 
studies that represent key projects for genome-wide Ribo-
seq ORF identification in the last five years (Supplementary 
Table S1). We retrieved ORF exonic coordinates -when 
available- and ORF sequences, collecting a total set of 
39,788 translated ORFs corresponding to 29,373 unique 
protein sequences. Only Ribo-seq ORFs found in long non-
coding RNAs (lncRNAs), alternative protein-coding frames 
and/or UTRs from protein-coding genes were selected, 
discarding annotated proteins, extensions/truncations of 
annotated isoforms, pseudogenic ORFs and circRNA ORFs. 
Each of the selected studies applied different minimum 
length cut-offs to define their Ribo-seq ORFs and only 4 of 
the studies considered near-cognate ORFs (ORFs starting 
with non-AUG initiation codons, see Box 3 and 
Supplementary Table S1). Hence, in order to maximize 
ORF replicability across studies we discarded 8,503 Ribo-
seq ORFs shorter than 16 amino acids and 10,412 Ribo-seq 
ORFs starting with near-cognate codons. 
    Next, for the five ORF datasets that were built on an older 
Human Genome assembly (GRCh37/hg19, Supplementary 
Table S1), we converted ORF coordinates to GRCh38/hg38 
using UCSC Liftover (Navarro Gonzalez et al., 2021). We 
remapped all translated ORF sequences to Ensembl 
Release v.101 transcriptome (August 2020, equivalent to 
GENCODE v37), generating a set of 8,805 unique ORFs 
after excluding 1,767 ORFs that could not be fully mapped to 
any transcript in this release. We note that the latter set 
includes 80 replicated Ribo-seq ORFs, i.e., ORFs detected 
in more than one study (Supplementary Table S8); 
GENCODE are currently examining these Ribo-seq ORFs 
and the potential transcript structures they would map to for 
potential inclusion. For 130 ORFs, the sequence could be 
mapped to more than one transcribed genomic region and 
the exact unique region was identified by combining the 
exonic coordinate data and/or the associated gene names 
annotated in each study. Moreover, we further excluded 
ORFs overlapping pseudogenes (423) or in-frame coding 
(CDS) sequences from protein-coding or nonsense-mediated 
decay transcripts (560) in the current transcriptome version, 
since the ORF datasets used older transcriptome releases 
and new protein-coding sequences and pseudogenes are 
newly annotated in Ensembl v.101 (Supplementary Table 
S4). Finally, in order to get a non-redundant list of translated 
ORFs for the Phase I, we adapted the clustering method of 
UniRef90 (UniProt, (The UniProt Consortium, 2021)) and 
collapsed overlapping ORFs with alternative start or stop 
codons in groups where multiple instances of ORF variants 
shared >= 90% of the linear amino acid sequence, 
considering the longest ORF as representative. If an ORF 
variant exhibited significant similarity to two or more non-
collapsed ORFs, the variant was multiply assigned to all 
possible cases. This resulted in a total of 7,264 collapsed 
Ribo-seq ORFs (Figure 2A), where only 549 of the ORFs 
had more than one ORF variant –a total of 558 unique ORF 
sequence variants. The number of considered ORFs per 
study varied between 846 and 3,062. This substantial 
difference in detected ORFs is not necessarily a reflection of 
data quality or depth, but primarily the result of approach-
specific filtering presets or the number of replicate 
identifications required within each study. 
    For the Phase I, we selected a subset of 3,085 replicated 
Ribo-seq ORFs that are robustly translated in more than one 
study. A Ribo-seq ORF was considered as translated in a 
specific dataset if the main ORF sequence or any of the 
collapsed ORF variants was found in the ORF list generated 
by that study. 
 
ORF classification and transcript assignment 
Ribo-seq ORFs were classified into 6 different biotypes 
defined by the host transcript biotype and the relative 
position compared to annotated canonical protein-coding 
sequences (see Box 1). However, gene annotations usually 
contain several overlapping isoforms and 65.44% of the 
Ribo-seq ORFs could not be unambiguously mapped to a 
unique host isoform. For these cases, we assigned the 
transcript with the highest APPRIS score (Rodriguez et al., 
2018) as the most likely isoform that translates each ORF. If 
more than one transcript shared a similar APPRIS score, we 
further evaluated the Ensembl transcript support evidence 
(TSL) score. For 1,513 ORFs, the sequence could be still 
mapped to several transcript sequences with equal support 
evidence. However, for these cases the selection of different 
isoforms did not affect the assigned ORF biotype or the 
exonic coordinates and we randomly selected one of the 
transcripts as host. All possible Ensembl transcript and gene 
IDs compatible with each ORF sequence, as well as the IDs 
of the selected host transcripts, are described in 
Supplementary Tables S2 and S3. 
 
Multiple-species alignment and PhyloCSF 
We downloaded previously generated multiple-genome 
alignments for 120 mammals (Hecker and Hiller, 2020) and 
we extracted aligned regions for each of the human Ribo-seq 
ORFs. Only species where the ORF region could be fully 
aligned were included in each alignment. As a result, 99.5% 
and 97.23% of the ORFs were aligned to at least one 
primate species and a non-primate mammalian species 
respectively. Next, we assessed the conservation of 
replicated Ribo-seq ORFs by comparing the patterns of 
codon evolution in different mammalian species using 
PhyloCSF (Lin et al., 2011) with default parameters. For 
comparison, we additionally built multiple alignments and ran 
PhyloCSF for a set of 531 annotated CDS sequences 
shorter than 100 amino acids, taking the longest CDS per 
gene (sCDSs). 
 
Analysis of proteomics datasets 
We searched for additional evidence of Ribo-seq ORF 
protein production by collecting 16 published datasets that 
identified peptides mapping to non-annotated protein-coding 
regions using different mass-spectrometry (MS) approaches 
(e.g. standard MS/MS, peptidome isolation, HLA peptidome 
isolation and targeted SRM proteomics, Supplementary 
Table S7). Peptides were retrieved from the corresponding 
Supplementary Materials and were remapped to the full set 
of Ribo-seq ORF sequences. Peptides that uniquely mapped 
to a Ribo-seq ORF and did not map to any annotated 
protein-coding sequence were retained as MS evidence. 
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